Beijing Biostar Pharmaceuticals Co., Ltd. (02563, BIOSTAR PHARM-B) issued a supplemental circular ahead of its 26 June 2026 annual general meeting (AGM), announcing three key changes to the agenda.

1. Connected-transaction resolution removed • A proposed ordinary resolution to ratify 2025 connected transactions was withdrawn after management identified it as a drafting error. • The only connected dealing in 2025 was a procurement from Beijing Baygen Technology Co., Ltd. totaling RMB2.67 million, well below the 5% threshold under HKEX Listing Rule 14A.76, and therefore exempt from shareholder approval.

2. Auditor re-appointment details updated • Re-appointment of Zhiwei Certified Public Accountants (Special General Partnership) for FY-2026 remains on the ballot. • Total audit remuneration will not exceed RMB1.48 million, with the board authorised to finalise the exact amount.

3. Share Option Scheme resolutions withdrawn • Two special resolutions related to adoption of a new Share Option Scheme have been pulled to allow further refinement of the plan. • Management intends to submit the revised scheme at a future shareholders’ meeting.

Proxy and meeting logistics • No new proxy form will be issued; shareholders may continue to use the original form circulated on 28 May 2026. • All other resolutions in the initial notice remain valid and will be put to vote at the AGM, scheduled for 3:00 p.m. on 26 June 2026 at the company’s Beijing headquarters.

The board stated that the withdrawals do not impact the group’s operations or financial position.